Wall Street Breakfast Podcast: Nebius Rockets On $17B Microsoft Deal

Nebius Group (NBIS) surged 49% pre-market after securing a significant $17.4 billion, five-year agreement with Microsoft (MSFT) to provide AI infrastructure, a deal potentially expanding to $19.4 billion. Concurrently, Novartis (NVS) announced the acquisition of Tourmaline Bio (TRML) for $1.4 billion in cash, representing a 59% premium, to gain its cardiovascular drug pacibekitug. Separately, the NFL's YouTube (GOOG) debut attracted 17.3 million viewers, though the specific measurement methodology used by Nielsen for streaming content drew criticism from traditional broadcasters, highlighting ongoing issues with cross-platform viewership data standardization.

Analysis

Nebius Group (NBIS) experienced a 49% pre-market surge following the announcement of a monumental five-year, $17.4 billion agreement with Microsoft to provide dedicated artificial intelligence infrastructure. This contract, which has the potential to expand to $19.4 billion, will be serviced from a new data center in New Jersey and represents a transformative revenue stream for Nebius, cementing its role as a key supplier in the AI ecosystem while highlighting the massive capital commitments major tech firms are making to secure computing capacity. In the M&A space, Novartis is set to acquire Tourmaline Bio (TRML) in an all-cash transaction valued at $1.4 billion, or $48.00 per share. The deal, representing a significant 59% premium to Tourmaline's recent closing price, is strategically driven by the potential of TRML's cardiovascular drug candidate, pacibekitug, and is expected to close in Q4. Meanwhile, the media landscape saw the NFL's debut on Google's YouTube draw a substantial 17.3 million average minute audience, but the event was marred by industry friction as rivals like Fox Sports criticized Nielsen's non-transparent viewership measurement for streaming, exposing an ongoing conflict over data standardization between digital platforms and traditional broadcasters.

Key Decisions for Investors

• The multi-year, $17.4 billion AI infrastructure contract significantly de-risks Nebius Group's (NBIS) forward revenue and validates its market position, warranting a re-evaluation of its long-term valuation based on this secured income stream.
• For Tourmaline Bio (TRML) investors, the all-cash acquisition by Novartis at a 59% premium effectively caps the stock's value near the $48.00 offer price, shifting the investment thesis to deal-closing risk and timeline rather than fundamental performance.
• Investors in media companies like Google (GOOG) and their broadcast rivals should monitor the dispute over Nielsen's streaming viewership metrics, as its resolution will be critical for accurately valuing sports rights and advertising revenue across all platforms.
• The 58% pre-market rally in Wolfspeed (WOLF) on its court-approved emergence from Chapter 11 represents a significant de-risking event, prompting a need to analyze the company's new capital structure and forward-looking operational plan.